| Literature DB >> 27399653 |
Bin Zhang1,2,3,4, Yaping Chen5, Qiang Shen6, Guiyan Liu7, Jingxue Ye8,9,10,11, Guibo Sun12,13,14,15, Xiaobo Sun16,17,18,19.
Abstract
Hyperglycemia, as well as diabetes mellitus, has been shown to trigger cardiac cell apoptosis. We have previously demonstrated that myricitrin prevents endothelial cell apoptosis. However, whether myricitrin can attenuate H9c2 cell apoptosis remains unknown. In this study, we established an experiment model in H9c2 cells exposed to high glucose. We tested the hypothesis that myricitrin may inhibit high glucose (HG)-induced cardiac cell apoptosis as determined by TUNEL staining. Furthermore, myricitrin promoted antioxidative enzyme production, suppressed high glucose-induced reactive oxygen species (ROS) production and decreased mitochondrial membrane potential (MMP) in H9c2 cells. This agent significantly inhibited apoptotic protein expression, activated Akt and facilitated the transcription of NF-E2-related factor 2 (Nrf2)-mediated protein (heme oxygenase-1 (HO-1) and quinone oxidoreductase 1 (NQO-1) expression as determined by Western blotting. Significantly, an Akt inhibitor (LY294002) or HO-1 inhibitor (ZnPP) not only inhibited myricitrin-induced HO-1/NQO-1 upregulation but also alleviated its anti-apoptotic effects. In summary, these observations demonstrate that myricitrin activates Nrf2-mediated anti-oxidant signaling and attenuates H9c2 cell apoptosis induced by high glucose via activation of Akt signaling.Entities:
Keywords: H9c2 cell; apoptosis; hyperglycemia; oxidative stress; reactive oxygen species
Mesh:
Substances:
Year: 2016 PMID: 27399653 PMCID: PMC6274128 DOI: 10.3390/molecules21070880
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structure of myricitrin and the effects of myricitrin on HG-induced H9c2 cell death and morphological changes. (A) The chemical structure of myricitrin; (B) Cell viability was assessed by the MTT assay. H9c2 cells were exposed to 33 mM glucose for 48 h in the presence or absence (Control) of myricitrin (25 μg/mL); (C) Representative photomicrographs of H9c2 cells in various experimental groups with or without high glucose treatment. The bar represents 200 μm. Values are represented as the mean ± SD (n = 9). The results were representative of three independent experiments. * p < 0.01 vs. control; Δ p < 0.05 vs. HG; # p < 0.01 vs. HG.
Figure 2The effects of myricitrin on antioxidant enzyme activity in HG-induced H9c2 cells: SOD (A); CAT (B); GSH-Px (C); LDH (D); and MDA (E) activities were determined using the kits. Values are represented as the mean ± SD (n = 9). The results were representative of three independent experiments. * p < 0.01 vs. control; # p < 0.01 vs. HG.
Figure 3The effects of myricitrin on HG-induced ROS production and MMP (ΔΨm) reduction in H9c2 cells. (A) Fluorescence images and bar diagram showed the ROS levels in the H9c2 cells; the fluorescence intensity of ROS was measured by a fluorescence microplate reader. The bar represents 200 μm; (B) Representative images and quantitative analysis of JC-1 staining. Treating H9c2 cells with HG caused a significant decrease in the in the ratio of red to green fluorescence intensity, which is a sign of the early stages of cell apoptosis. The bar represents 400 μm. Values are represented as the mean ± SD; n = 10 wells per group. * p < 0.01 vs. control; # p < 0.01 vs. HG.
Figure 4Protection effects of myricitrin against HG-induced H9c2 cells apoptosis. Pretreatment with myricitrin (25 μg/mL) for 24 h prior to HG, H9c2 cardiomyocytes apoptosis was assessed using TUNEL staining. (A) Representative images of TUNEL-positive nuclei in green fluorescent color and total nuclei staining with Propidium iodide (PI); (B) Bar diagram showing the relative proportion of TUNEL-positive cells (n = 5); (C) Western blot analysis of cleaved caspase-3, cleaved caspase-9, Bax and Bcl-2 expressions; (D) The ratio of Bax to Bcl-2 in various groups; (E) Cleaved caspase-3 and caspase-9 expressions in different groups. Values are represented as the mean ± SD (n = 3). * p < 0.01 vs. control; # p < 0.01 vs. HG.
Figure 5Myricitrin exerts its effects by activating the PI3K/Akt pathway and Nrf2/ARE signaling. (A) Representative immunoblots of the protein expression of phospho- and total Akt, HO-1, NQO-1 and Nrf2; (B) Cell viability in H9c2 cells with 4 h pretreatment of the PI3K inhibitor LY294002 (50 μM) was evaluated by MTT assay. n = 10 wells per group. Quantitative analysis of Nrf2, NQO-1 and HO-1 expression levels (C) and the statistical analysis of the p-Akt/Akt expression level relative to the control group (D). Values are represented as the mean ± SD (n = 3). * p < 0.01 vs. control; # p < 0.01 vs. HG; Δ p < 0.05 vs. HG + Myr. + represents treated; − represents untreated.
Figure 6The anti-apoptotic effects of myricitrin were attenuated by HO-1 inhibitor. The expressions of target protein were evaluated by Western blot assay. (A) Representative immunoblots of the protein expression of HO-1, cleaved caspase-3, Bax and Bcl-2; (B) Cell viability of H9c2 cells with 48 h pretreatment of ZnPP (10 μM) was evaluated by MTT assay. n = 10 wells per group. Quantitative analysis of HO-1 (C) and cleaved caspase-3 expression levels (D) and the statistical analysis of the Bax/Bcl-2 expression level relative to the control group (E). Values are represented as the mean ± SD (n = 3). * p < 0.01 vs. control; # p < 0.01 vs. HG; Δ p < 0.05 vs. HG + Myr. + represents treated; − represents untreated.
Figure 7Schematic of the mechanism of myricitrin inhibition of HG-induced apoptosis via activation of PI3K/Akt signaling and up-regulation of HO-1 and NQO-1 in H9c2 cells.